Cambridge Epigenetix
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Trinity Building Chesterford Researc...Phone Number
+44 1223804260Website
www.cambridge-epigenetix.comRevenue
$8.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cambridge Epigenetix
biomodal specializes in advanced multiomics technologies that enable the simultaneous capture of genetic and epigenetic information from a single biological sample. Their innovative duet multiomics solutions, evoC and +modC, facilitate in-depth analysis essential for research in cancer, neurodegenerative diseases, and precision medicine. By providing insights into the 6-base genome, the company empowers researchers to better understand normal and disease biology. Their products are designed for scientists and researchers in the fields of genomics and biotechnology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cambridge Epigenetix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cambridge Epigenetix
Check if Cambridge Epigenetix has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Cambridge Epigenetix, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Cambridge Epigenetix has new funding data
Check out if Cambridge Epigenetix is spiking on competitors!
Earning: See what the market has to say on Cambridge Epigenetix recently announced quarterly report
Product Launch: Get notified when Cambridge Epigenetix launches new products
Click to see if Cambridge Epigenetix had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Cambridge Epigenetix
Find 2 more new buyers
Compare Similar Companies to Cambridge Epigenetix
Compare insights from companies similar to Cambridge Epigenetix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cambridge Epigenetix
$8.9M
11-50
Private
$144.5M
2012
N/A
Company Profile Activity
Activity Insights
Cambridge Epigenetix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cambridge Epigenetix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cambridge Epigenetix.
Cambridge Epigenetix financials insights
Gather financial insights about Cambridge Epigenetix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$5.5M
2016
Series B
$21M
2018
Series C
$30M
2021
Series D
$88M
Cambridge Epigenetix Tech Stack
A closer look at the technologies used by Cambridge Epigenetix
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Cambridge Epigenetix News & Media
Latham & Watkins Advises on Cambridge Epigenetix US$88 Million Series D Round
London emerging companies team represents lead investor in financing to advance best-in-class DNA sequencing technology platform.Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours
CAMBRIDGE, England--(BUSINESS WIRE)--Cambridge Epigenetix Ltd, a pioneer in the development and application of epigenetic technologies, today announces its discovery and development programme for a test to detect colorectal and other cancers. This follows completion of a c. $30 million funding round, as well as the acquisition of exclusive patent rights for its epigenetic sequencing platform. Epigenetic changes act as a control layer for the genome and can alter gene expression, but not the gen
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cambridge Epigenetix
Sign Up For FreeTo access detailed company insights
biomodal specializes in advanced multiomics technologies that enable the simultaneous capture of genetic and epigenetic information from a single biological sample. Their innovative duet multiomics solutions, evoC and +modC, facilitate in-depth analysis essential for research in cancer, neurodegenerative diseases, and precision medicine. By providi... Read More
